

## Editors Note

---

Dear Readers,

We are gratified to see that the inaugural **Clinical Trials Corner** was the most viewed article of the *Journal of Huntington's Disease* during the October 2017 period and was one of the top ten most-viewed articles of 2017. We interpret this as evidence of a desire in our community for well-curated and comprehensive information about clinical trials in HD. Drs Wild and Rodrigues have done a wonderful job preparing this new JHD feature and have succeeded in presenting this very complex information in an accessible format. The Clinical Trials Corner will be a recurring, open-access feature in JHD. The current issue includes a summary table, **Table 1**, which lists the trials discussed in detail in the previous edition, and which will be updated in each successive Corner. We trust that our readers will continue to find this exciting new feature of JHD useful and informative.

Sincerely,

Leslie and Blair

Leslie Thompson and Blair R. Leavitt

Editors-in-Chief

**The Journal of Huntington's Disease**

# Huntington's Disease Clinical Trials Corner: MMM YYYY

Filipe B. Rodrigues<sup>a,b,c</sup> and Edward J. Wild<sup>a,\*</sup>

<sup>a</sup>Huntington's Disease Centre, University College London, UK

<sup>b</sup>Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal

<sup>c</sup>Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal

**Abstract.** In the second edition of the Huntington's Disease Clinical Trials Corner we list all currently registered and ongoing clinical trials, summarise the top-line results of the recently-announced IONIS-HTT<sub>RX</sub> trial (NCT02519036), expand on Wave Life Sciences' PRECISION-HD1 (NCT03225833) and PRECISION-HD2 (NCT03225846), and cover one recently finished trial: the FIRST-HD deutetrabenazine trial (NCT01795859).

Keywords: Huntington disease, clinical trials

## INTRODUCTION

The Huntington's Disease Clinical Trials Corner is a regular section devoted to highlighting ongoing and recently completed clinical trials in Huntington's disease (HD). Clinical trials previously reviewed by the Huntington's Disease Clinical Trials Corner are listed in Table 1.

Table 1  
Clinical trials previously reviewed by the Huntington's Disease Clinical Trials Corner

Registration ID	Trial name	Intervention	Edition
NCT02519036	IONIS-HTTR <sub>x</sub>	IONIS-HTT <sub>Rx</sub>	September
NCT02215616	LEGATO-HD	Laquinimod	2017(6)
NCT02197130	Amaryllis	PF-02545920	
NCT02006472	Pride-HD	Pridopidine	

In this edition, we summarise the recently-announced top-line results from the phase 1b/2a IONIS-HTT<sub>RX</sub> huntingtin-lowering antisense oligonucleotide (ASO) trial (NCT02519036) [1]; highlight the new Wave Life Sciences allele-selective ASO trials, PRECISION-HD1 (NCT03225833) [2]

\*Correspondence to: Edward J. Wild, UCL Huntington's Disease Centre, Russell Square 10-12, London, WC1B 5EH, UK. E-mail: e.wild@ucl.ac.uk.

and PRECISION-HD2 (NCT03225846) [3], and summarise the results of the FIRST-HD (NCT01795859) [4, 5] trial of deutetrabenazine.

Finally we tabulate all currently registered and ongoing clinical trials in Tables 2 to 4. For further details on the methodology used please refer to the September 2017 edition of Huntington's Disease Clinical Trials Corner [6].

If you would like to draw attention to specific trials, please feel free to email us at: E-mail: f.rodrigues@ucl.ac.uk. and E-mail: e.wild@ucl.ac.uk.

## BREAKING NEWS

December 11th 2017 saw the initial announcement of top-line results from the first-in-human phase 1b/2a trial of IONIS-HTT<sub>RX</sub>, the first ASO designed to lower huntingtin protein (HTT) to be tested in people with HD (NCT02519036) [1]. The announcement came in the form of a press release from the sponsor, Ionis Pharmaceuticals [7], and was followed by substantial media coverage [8, 9]. As we detailed in the previous Clinical Trials Corner [6], the trial had safety as its primary endpoint. Encouragingly, the release reported that "the safety and tolerability profile ...

Table 2

Ongoing pharmacological clinical trials registered at the World Health Organization (WHO) International Clinical Trials Research Platform (ICTRP) for people with Huntington's disease (HD).  
N/S, not specified; PD, Parkinson's disease; VMAT2, Vesicular Monoamine Transporter 2. New trials since the last Clinical Trials Corner are indicated by\*

Registration ID	Trial name	Intervention	Mechanism of Action	Population	Comparison	Main outcome	Study design	Estimated Enrolment	Sponsor	Location
NCT03342053*	IONIS-HTT <sub>RX</sub> OLE	ISIS 443139	Allele-nonspecific antisense oligonucleotide	HD	None	Safety and tolerability at 74 weeks	Open label extension	46	Ionis Pharmaceuticals Inc.	Canada, Germany and UK (multi-centre)
NCT03225833*	PRECISION-HD1	WVE-120102	Allele-selective antisense oligonucleotide	HD	Placebo	Safety and tolerability at 1 and 120 days	Randomized, double-blind, placebo-controlled, combined single ascending dose/multiple ascending dose trial	48	Wave Life Sciences Ltd.	Canada and Poland (multi-centre)
NCT03225846*	PRECISION-HD2	WVE-120102	Allele-selective antisense oligonucleotide	HD	Placebo	Safety and tolerability at 1 and 120 days	Randomized, double-blind, placebo-controlled, combined single ascending dose/multiple ascending dose trial	48	Wave Life Sciences Ltd.	Canada and Poland (multi-centre)
EUCTR2016-003730-25-NL	CHALLENGE-HD	SBT-020	Mitochondria-targeted cytoprotective peptide	Early HD	Placebo	Safety and tolerability at 7 and 28 days	Randomized, double-blind, placebo-controlled, parallel trial	24	Stealth Biotherapeutics	Netherlands (single centre)
NCT03019289	-	Pridopidine	Dopaminergic stabilizer	Healthy individuals and HD	None	Pharmacodynamic at 1 day	Single dose, open-label, single group trial	38	Teva Branded Pharmaceutical Products, R&D Inc.	Germany (single centre)
NCT02453061	TRIHEP 3	Triheptanoin	Anaplerotic therapy	HD	Placebo	Pharmacodynamic efficacy at 6 months	Randomized, double-blind, placebo-controlled, parallel trial	100	Institut National de la Santé Et de la Recherche Médicale, Ultragenyx Pharmaceutical Inc	France, Netherlands (multi centre)

(Continued)

Table 2  
(Continued)

Registration ID	Trial name	Intervention	Mechanism of Action	Population	Comparison	Main outcome	Study design	Estimated Enrolment	Sponsor	Location
NCT02509793	–	Tetrabenazine	VMAT2 inhibitor	HD with impulsivity	None	Cognitive and behavioural effects at 8 weeks	Single group, open-label trial	20	University of Texas Health Science Center, and H. Lundbeck A/S	USA (single centre)
NCT02507284	STAIR	SRX246	Vasopressin 1a Receptor Antagonist	Early and moderate HD with irritability	Placebo	Feasibility at 12 weeks	Randomized, double-blind, placebo-controlled, parallel trials	108	Azevan Pharmaceuticals, National Institute of Neurological Disorders and Stroke (NINDS), and NeuroNEXT Network	USA (multi centre)
NCT02494778	Open PRIDE-HD	Pridopidine	Dopaminergic stabilizer	PRIDE-HD completers	None	Safety at 104 weeks	Single group, open label extension of PRIDE-HD	300	Teva Branded Pharmaceutical Products, R&D Inc.	Australia, Austria, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Russia, UK, USA (multi centre)
NCT02481674	SIGNAL	VX15/2503	Anti-semaphorin 4D monoclonal antibody	Late premanifest or early HD	Placebo	Safety and tolerability at 15 and 21 months	Randomized, double-blind, placebo-controlled, parallel trial	116	Vaccinex Inc., Huntington Study Group	USA (multi centre)
NCT02336633	REVHD	Resveratrol	Dietary supplement	HD	Placebo	Neuroimaging biomarkers at 1 year	Randomized, double-blind, placebo-controlled, parallel trial	102	Assistance Publique – Hôpitaux de Paris	France (multi centre)

NCT02215616	LEGATO-HD	Laquinimod	Immunomodulatory molecule	HD	Placebo	Efficacy at 1, 3, 6, and 12 months	Randomized, double-blind, placebo-controlled, parallel trial	400	Teva Branded Pharmaceutical Products, R&D Inc.	Canada, Czech Republic, France, Germany, India, Israel, Italy, Netherlands, Portugal, Russia, Spain, UK, USA (multi centre)
EUCTR2013-002545-10-SE	OSU6162 Open1309	(-)-OSU616	Monoaminergic stabilizer	HD, PD, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy	None	Safety at 3, 6 and 12 months	Single group, open-label trial	240	A. Carlsson Research AB	Sweden (multi centre)
NCT00652457	MEM-HD	Memantine	NMDA receptor antagonist	HD and memory or concentration difficulties	Placebo	Efficacy at 3 and 6 months	Randomized, double-blind, placebo-controlled, cross-over trial	60	University of California, San Diego, Forest Laboratories	USA (multi centre)
NCT00632645	NEUROHD	Olanzapine	Dopamine agonist	HD with motor or behavioural symptoms	Tetrabenazine or tiapride	Efficacy at 12 months	Randomized, open-label, controlled, parallel trial	180	Assistance Publique – Hôpitaux de Paris,	France (single centre)
NCT01306929	OPEN-HART	Pridopidine	Dopaminergic stabilizer	HART or PRIDE-HD completers	None	Safety at 2 years	Single group, open label extension of HART	235	Teva Branded Pharmaceutical Products, R&D Inc.	Canada, USA (multi centre)
NCT00514774	UDCA-HD	Ursodiol	Bile acid	HD	Placebo	Safety, tolerability and pharmacokinetics at 35 days	Randomized, double-blind, placebo-controlled, parallel trial	21	Oregon Health and Science University, Huntington Study Group, Huntington Society of Canada	N/S
ACTRN12616001611415	VCAS-HD	Varenicline	Nicotinic acid receptor partial agonist	HD	Placebo	Efficacy at 10 weeks	Randomized, double-blind, placebo-controlled, parallel trial	40	University of Auckland	New Zealand (single centre)

Table 3

Ongoing invasive non-pharmacological clinical trials registered at the World Health Organization (WHO) International Clinical Trials Research Platform (ICTRP) for people with Huntington's disease (HD). AD, Alzheimer's disease; CBD; Corticobasal Degeneration; DBS, deep brain stimulation; ET, Essential Tremor; GP, Globus pallidus; HT, Holmes Tremor; MNC, mononuclear cells; MS, Multiple Sclerosis; PD, Parkinson's disease; TD, Tardive dyskinesia; WD, Wilson's disease. New trials since the last Clinical Trials Corner are indicated by\*

Registration ID	Trial name	Intervention	Mechanism of Action	Population	Comparison	Main outcome	Study design	Estimated Enrolment	Sponsor	Location
NCT03252535*	ADORE-HD	Cellavita	Stem cell therapy	HD	Placebo	Efficacy at 120 days	Randomized, double-blind, placebo-controlled, parallel trial	35	Azidus Brasil	Brazil (single centre)
NCT03297177*	–	Autologous stem/stromal cells	Autologous stem/stromal cell injection	HD, AD, PD, CBD, MS	None	Safety at 5 years	Single group, open-label trial	300	Healeon Medical Inc, Global Alliance for Regenerative Medicine, Regeneris Medical	USA and Honduras (multi-centre)
NCT02535884	HD-DBS	GP DBS	Deep brain stimulation	Moderate HD with chorea	Sham intervention	Efficacy at 12 months	Randomized, double-blind, sham-controlled, parallel trial	50	Heinrich-Heine University, KKS Netzwerk, Medtronic, The George Institute, EHDN, CHDI Foundation, Inc.	Austria, Germany, Switzerland (multi centre)
NCT01834053	BMACHC	Bone Marrow Derived MNC transplant	Bone marrow transplant	HD with chorea	None	Cognitive and behavioural effects at 6 months	Single group, open-label trial	50	Chaitanya Hospital, Pune	India (single centre)
NCT02263430	–	GP DBS	Deep brain stimulation	HD with chorea	Sham stimulation	Efficacy at 12 months	Randomized, double-blind, placebo-controlled, parallel trial	8	Beijing Pins Medical Co., Ltd, Beijing Tiantan Hospital	China (single centre)
NCT02252380	–	Magnetic Resonance Guided Focused Ultrasound	Extracranial stereotactic radioablation	HD, ET, HT, PD, WD, dystonia, TD, or orofacial dyskinesias	None	Adverse events after the procedure	Single group, open-label trial	10	InSightec	Canada (single centre)

Table 4

Ongoing non-invasive non-pharmacological clinical trials registered at the World Health Organization (WHO) International Clinical Trials Research Platform (ICTRP) for people with Huntington's disease (HD). AD, Alzheimer's disease; ALS, Amyotrophic Lateral Sclerosis; ET, Essential Tremor; HT, Holmes Tremor; MS, Multiple Sclerosis; PD, Parkinson's disease; TD, Tardive dyskinesia. New trials since the last Clinical Trials Corner are indicated by\*

Registration ID	Trial name	Intervention	Mechanism of Action	Population	Comparison	Main outcome	Study design	Estimated Enrolment	Sponsor	Location
NCT03344601*	PACE-HD	Supported structured aerobic exercise training program	Physiotherapy	HD	Activity as usual	Data completeness, recruitment, retention, safety, adherence, fidelity and acceptability at 12 months	Nested open-label, randomized controlled parallel trial	120	Cardiff University and CHDI Foundation, Inc	Germany, Spain and USA (multi centre)
NCT03306888*	–	Physical Activity Coaching Intervention	Physiotherapy	Premanifest and early HD	None	Change in physical activity at 4 months	Single group, open-label trial	14	Columbia University	USA (single centre)
ACTRN12617001269325*	–	Swallowing skill training	Speech and language therapy	HD and ALS	None	Swallowing function and quality of life at 2 weeks	Single group, open-label trial	54	University of Canterbury	New Zealand (single centre)
NCT02990676	CogTrainHD	Computerised Cognitive Training	Cognitive training	HD	No intervention	Feasibility at 4 years	Open-label, controlled, parallel trial	50	Cardiff University	UK (single centre)
NCT01879267	–	Endurance exercise training	Physiotherapy	HD and healthy controls	None	Motor effects 6 months	Single group, open-label trial with parallel healthy controls arm	40	University of Zurich	Switzerland (single centre)
NCT02464293	–	Mindfulness-based Cognitive Therapy	Cognitive therapy	Premanifest and early HD with behavioural symptoms	None	Behavioural effect at 2 weeks, 3 months and 1 year	Single group, open-label trial	16	Lancaster University, Central Manchester University Hospitals NHS Foundation Trust	UK (single centre)

(Continued)

Table 4  
(Continued)

Registration ID	Trial name	Intervention	Mechanism of Action	Population	Comparison	Main outcome	Study design	Estimated Enrolment	Sponsor	Location
NCT02216474	–	tDCS	Transcranial magnetic stimulation	HD or Tourette Syndrome	Sham stimulation	Efficacy at 2 weeks	Randomized, double-blind, placebo-controlled, cross-over trial	100	Birmingham and Solihull Mental Health NHS Foundation Trust, University of Birmingham	UK (single centre)
NCT02750982	–	Laughter Therapy	Cognitive therapy	HD, AD, ALS, brain injury, MS, PD, post/stroke or spinal cord injury	None	Behavioural effects at 8 weeks	Single group, open-label trial	24	Brown, Theodore R., M.D., MPH	USA (single centre)
NCT01602276	–	tDCS	Transcranial magnetic stimulation	Subcortical brain damage, including HD	Sham stimulation	Efficacy at 1 month	Randomized, single-blind, placebo-controlled, cross-over trial, with parallel healthy control arm	150	Johns Hopkins University	USA (single centre)



68 supports continued development". More excitingly,  
69 dose-dependent reductions in cerebrospinal fluid  
70 mutant huntingtin concentration were seen in patients  
71 who received IONIS-HTT<sub>Rx</sub>. C. Frank Bennett,  
72 Ionis' Senior Vice President of Research, noted  
73 that the mutant huntingtin reduction "substantially  
74 exceeded our expectations". As a result, Roche has  
75 exercised its option to license the drug and will now  
76 be responsible for future development of the program.  
77 In a separate statement for the HD community, Ionis  
78 confirmed that an efficacy trial was planned and that  
79 "future studies for the program will be conducted  
80 globally, including in the US" [10]. Meanwhile, an  
81 open-label extension is underway for the 46 partic-  
82 ipants who took part in the original study (Table 2,  
83 NCT03342053) [11].

84 This is a significant positive announcement in  
85 a therapeutic program with substantial promise for  
86 disease-modification in HD. Naturally, it will need to  
87 be supported by release of more detailed data from the  
88 trial, and peer-reviewed publication of the results. The  
89 sponsor has committed to supplying these updates in  
90 the first half of 2018 [10].

## 91 ONGOING CLINICAL TRIALS

92 A list of all ongoing clinical trials is given in  
93 Tables 2, 3 and 4.

### 94 *PRECISION-HD1 (NCT03225833) and* 95 *PRECISION-HD2 (NCT03225846)*

96 *Study titles:* A Multicenter, Randomized, Double-  
97 blind, Placebo-controlled, Phase 1b/2a Study of  
98 WVE-120101 Administered Intrathecally in Patients  
99 With Huntington's Disease [2] and A Multicen-  
100 ter, Randomized, Double-blind, Placebo-controlled,  
101 Phase 1b/2a Study of WVE-120102 Adminis-  
102 tered Intrathecally in Patients With Huntington's  
103 Disease [3].

104 *Intervention:* Respectively WVE-120101 and  
105 WVE-120102, two distinct allele-selective ASOs  
106 [12].

107 *Description:* The PRECISION-HD trials aim to  
108 compare the safety, tolerability, pharmacokinetics  
109 and pharmacodynamics of single and multiple  
110 ascending doses of WVE-120101 and WVE-120102,  
111 respectively, administered intrathecally, comparing  
112 with intrathecal placebo, for disease modification  
113 in people with HD (i.e. clinical diagnostic motor  
114 features of HD, a Unified Huntington's Disease Rat-  
115 ing Scale (UHDRS) Diagnostic Confidence Level of

116 4, and a UHDRS Total Functional Capacity (TFC)  
117 between 13 and 7, inclusively) who carry a targeted  
118 single nucleotide polymorphism (SNP) rs362307 or  
119 rs362331, respectively, and are aged between 25 and  
120 65 years old.

121 These trials are phase 1b/2a, multi-centre, interna-  
122 tional, randomized, placebo controlled, double-blind,  
123 parallel studies. They have a combined single ascend-  
124 ing dose/multiple ascending dose design, comprising  
125 four cohorts of progressively higher ASO doses. In  
126 each cohort, participants will be allocated to receive  
127 a single dosage or three dosages of the ASO or a  
128 placebo. Each trial has the recruitment target of 48  
129 participants; currently recruitment is open in Canada  
130 and Poland. The WVE-120101 and WVE-120102  
131 compounds are ASOs targeting the pre-mRNA tran-  
132 script of two allelic variants linked to the expanded  
133 CAG repeat tract in the *HTT* gene, with the aim of  
134 selectively reducing the production of mutant hunt-  
135 ingtin protein while leaving the level of wild-type  
136 huntingtin protein relatively unaltered. Each partici-  
137 pant's involvement will last for 210 days.

138 The primary outcome is safety and tolerabil-  
139 ity at 210 days. The secondary outcomes involve  
140 pharmacokinetic measurements in plasma; pharma-  
141 codynamic measures in cerebrospinal fluid, including  
142 mutant huntingtin; and the UHDRS TFC.

143 *Sponsors/funders:* Wave Life Sciences Ltd.

144 *Comments:* The CAG expansion in the *HTT* gene  
145 is frequently allelically linked to three different SNPs  
146 that collectively are thought to be present in at least  
147 80% of the gene expansion carriers of European  
148 ancestry [13]. These two trials are running in par-  
149 allel and will target two of these SNPs. Participants'  
150 DNA samples will first be screened for the presence  
151 of one of both SNPs, and then further tested to estab-  
152 lish whether either SNP is allelic to the *HTT* CAG  
153 expansion.

154 While the molecule tested in the IONIS-HTT<sub>Rx</sub>  
155 trial and its open-label extension (*NCT02519036*) [1]  
156 is expected to reduce the translation of both wild-type  
157 and mutant pre-mRNA, the PRECISION-HD ASOs  
158 were designed to target selectively the mutant pre-  
159 mRNA and mark it for degradation by RNase H. This  
160 selectivity is attained by means of targeting the most  
161 frequent SNPs associated with mutant *HTT*. The the-  
162 oretical advantage is that this may reduce the potential  
163 long-term risk stemming from lowering of wild-type  
164 huntingtin and associated loss-of-function [14].

165 However, it is also worth noting that no safety  
166 concerns have so far been identified in the ongoing,  
167 allele-nonselective IONIS-HTT<sub>Rx</sub> programme [6].

Wave's platform is also distinguished by the ability to specify the chirality of each phosphorothioate bond in the ASO backbone, which has the potential to improve characteristics such as stability and target mRNA degradation [15]. Each approach – both in terms of chiral purity and allele-selectivity – has potential advantages and disadvantages [12]. Each SNP-selective compound will have to go through independent testing and approval; the testing process to establish suitability is novel and time-consuming; and some mutation-carriers will be ineligible by virtue of possessing no suitable SNPs.

Together, the Wave and IONIS platforms will be informative and provide safety and efficacy information relating to different HTT lowering approaches.

## COMPLETED CLINICAL TRIALS

### *FIRST-HD (NCT01795859)*

*Study title:* A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease [4, 16].

*Intervention:* Deutetrabenazine or SD-809, a vesicular monoamine transporter type 2 (VMAT2) selective inhibitor.

*Description:* The goal of FIRST-HD trial was to compare the efficacy and safety of oral deutetrabenazine against an oral placebo, both taken twice daily and titrated to optimal dosage, for symptomatic relief of chorea in adults with stage 1 to 3 manifest HD (i.e. motor signs characteristic of HD plus a *HTT* CAG repeat length  $\geq 36$  plus a UHDRS TFC  $\geq 5$ ) and with significant chorea (i.e. a UHDRS total maximum chorea score (TMC) of 8 or higher).

This trial was a phase 3, multi-centre, international, randomized, placebo controlled, double blind, parallel study. It recruited 90 participants from Canada and the United States. Participant involvement lasted for 13 weeks.

The primary outcome was change from baseline in the UHDRS TMC at weeks 9 and 12. The UHDRS TMC is a subscore of UHDRS total motor score (TMS) that only includes the chorea-related items, and ranges from 0 to 28. The secondary outcomes were the Patient Global Impression of Change (PGIC), the Clinician Global Impression Change (CGIC), the Short Form 36 Health Survey (SF-36), the Berg Balance Test (BBT), and adverse events.

*Sponsors/funders:* Teva Pharmaceutical Industries

*Results:* The trial was completed on December 2014 and the results published in July 2016 [16]. It showed deutetrabenazine to be superior to placebo in decreasing chorea associated with HD, objectively and subjectively, and to improve quality of life, but not balance. Interestingly, in a *post-hoc* analysis, dystonia subscores on TMS also lessened with deutetrabenazine. In regards to safety, tetrabenazine was comparable with placebo, with the exception of weight gain that was more prevalent in the active treatment arm. It is noteworthy that this study was not powered to investigate adverse events and further information is required to draw definitive conclusions about safety.

In April 2017, the FDA approved this drug for the treatment of chorea associated with HD. Like tetrabenazine, its label includes a contraindication for patients who are suicidal, or who have untreated or inadequately treated depression.

Deutetrabenazine is a modified version of tetrabenazine containing deuterium (i.e. a stable isotope of hydrogen with mass number of 2) in strategic positions. This modification is intended to provide better pharmacokinetic properties (i.e. slower enzymatic degradation) to this otherwise chemically-identical compound, due to stronger bonds between carbon and deuterium.

Still, little is known about how deutetrabenazine compares with tetrabenazine, an older VMAT2 inhibitor also approved by FDA. In ARC-HD - a multicentre, international, single arm, open label study – the Huntington Study Group explored the safety of switching overnight from a stable and efficacious dosage of tetrabenazine to deutetrabenazine (NCT01897896) [17]. In a preliminary report, about 50% of the sample had at least one adverse event, but the drug was well tolerated with low rates of neuropsychiatric adverse events [18].

Unfortunately no head-to-head blinded comparison has been made between these compounds or is planned. Indirect treatment comparisons showed no apparent efficacy difference [19]. The safety results are contradictory [19, 20], possibly due to a statistical artefact [21]. Overall these results call for close post-licensing surveillance to guide informed prescribing decisions.

## ACKNOWLEDGMENTS

The authors are supported by CHDI Foundation, Inc. (salary support to FBR for conduct of the

265 HDClarity study) and Medical Research Council UK  
266 (salary support to EJW).

## 267 CONFLICTS OF INTEREST

268 FBR and EJW are sub-investigators on  
269 LEGATO-HD (NCT02215616), IONIS HTT<sub>Rx</sub>  
270 (NCT02519036) and IONIS HTT<sub>Rx</sub> OLE  
271 (NCT03342053), and EJW was a sub-investigator on  
272 the Amaryllis study (NCT02197130). The authors  
273 did not make use of confidential or privileged infor-  
274 mation: all materials included in this manuscript  
275 were collected from publicly available sources. EJW  
276 has participated in scientific advisory boards with  
277 Hoffmann-La Roche Ltd, Ionis, Shire, GSK and  
278 Wave Life Sciences. All honoraria were paid through  
279 UCL Consultants Ltd, a wholly owned subsidiary  
280 of UCL. Their Host Institution, University College  
281 London Hospitals NHS Foundation Trust, has  
282 received funds as compensation for conducting  
283 clinical trials for Ionis Pharmaceuticals, Pfizer and  
284 Teva Pharmaceuticals.

## 285 REFERENCES

- 286 [1] Ionis Pharmaceuticals I. Safety, Tolerability, Pharma-  
287 cokinetics, and Pharmacodynamics of IONIS-HTTRx in  
288 Patients With Early Manifest Huntington's Disease. [https://](https://ClinicalTrials.gov/show/NCT02519036)  
289 [ClinicalTrials.gov/show/NCT02519036](https://ClinicalTrials.gov/show/NCT02519036); 2015.
- 290 [2] Wave Life Sciences. Safety and Tolerability of WVE-  
291 120101 in Patients With Huntington's Disease. [https://](https://ClinicalTrials.gov/show/NCT03225833)  
292 [ClinicalTrials.gov/show/NCT03225833](https://ClinicalTrials.gov/show/NCT03225833); 2017.
- 293 [3] Wave Life Sciences. Safety and Tolerability of WVE-  
294 120102 in Patients With Huntington's Disease. [https://](https://ClinicalTrials.gov/show/NCT03225846)  
295 [ClinicalTrials.gov/show/NCT03225846](https://ClinicalTrials.gov/show/NCT03225846); 2017.
- 296 [4] Teva Pharmaceutical Industries. First Time Use of SD-  
297 809 in Huntington Disease. [https://ClinicalTrials.gov/show/](https://ClinicalTrials.gov/show/NCT01795859)  
298 [NCT01795859](https://ClinicalTrials.gov/show/NCT01795859); 2013.
- 299 [5] Huntington Study Group. Effect of deutetrabenazine on  
300 chorea among patients with huntington disease: A random-  
301 ized clinical trial. *Jama*. 2016;316(1):40-50.
- 302 [6] Rodrigues FB, Wild EJ. Clinical trials corner: September  
303 2017. *J Huntingtons Dis*. 2017;6(3):255-63.
- 304 [7] Ionis Pharmaceuticals I. Ionis Pharmaceuticals Licenses  
305 IONIS-HTT Rx to Partner Following Successful Phase  
306 1/2a Study in Patients with Huntington's Disease  
307 2017 [Available from: [http://ir.ionispharma.com/news-309](http://ir.ionispharma.com/news-releases/news-release-details/ionis-pharmaceuticals-licens-308 es-ionis-htt-rx-partner-following)  
308 releases/news-release-details/ionis-pharmaceuticals-licens-  
309 es-ionis-htt-rx-partner-following
- 310 [8] The Guardian. Excitement as trial shows Huntington's  
311 drug could slow progress of disease 2017 [Available from:  
312 [https://www.theguardian.com/science/2017/dec/11/excitement-314](https://www.theguardian.com/science/2017/dec/11/excitement-as-huntingtons-drug-shown-to-slow-progress-of-devas-313 tating-disease)  
314 as-huntingtons-drug-shown-to-slow-progress-of-devas-  
315 tating-disease
- 316 [9] CNN. Drug trial shows promising results to fight Hunt-  
317 ington's disease 2017 [Available from: [http://edition.cnn.318](http://edition.cnn.com/2017/12/11/health/huntingtons-disease-drug-trial-study/index.html)  
318 com/2017/12/11/health/huntingtons-disease-drug-trial-stu-  
319 dy/index.html
- 320 [10] HDSA. Breaking news: update on the status of the  
321 IONIS-HTTRX program and its future 2017 [Available  
322 from: [http://hdsa.org/news/breaking-news-update-on-the-323](http://hdsa.org/news/breaking-news-update-on-the-status-of-the-ionis-htrrx-program-and-its-future/)  
323 status-of-the-ionis-htrrx-program-and-its-future/
- 324 [11] Ionis Pharmaceuticals I. Study in Huntington's Dis-  
325 ease Patients Who Participated in Prior Investigational  
326 Studies of ISIS 443139. [https://ClinicalTrials.gov/show/327](https://ClinicalTrials.gov/show/NCT03342053)  
327 [NCT03342053](https://ClinicalTrials.gov/show/NCT03342053); 2017.
- 328 [12] Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in  
329 Huntington's disease. *Lancet Neurol*. 2017;16(10):837-47.
- 330 [13] Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC,  
331 Caron NS, et al. Huntingtin haplotypes provide prioritized  
332 target panels for allele-specific silencing in huntington dis-  
333 ease patients of european ancestry. *Molecular Therapy*.  
334 2015;23(11):1759-71.
- 335 [14] Saudou F, Humbert S. The biology of huntingtin. *Neuron*.  
336 2016;89(5):910-26.
- 337 [15] Iwamoto N, Butler DCD, Svrzikapa N, Mohapatra S,  
338 Zlatev I, Sah DWY, et al. Control of phosphorothioate  
339 stereochemistry substantially increases the efficacy of anti-  
340 sense oligonucleotides. *Nature biotechnology*. 2017;35(9):  
341 845-51.
- 342 [16] Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmond-  
343 son MC, et al. Effect of deutetrabenazine on chorea among  
344 patients with Huntington disease: A randomized clinical  
345 trial. *Jama*. 2016;316(1):40-50.
- 346 [17] Auspex Pharmaceuticals I. Alternatives for Reducing  
347 Chorea in HD. 2013.
- 348 [18] Frank S, Stamler D, Kayson E, Claassen DO, Colcher A,  
349 Davis C, et al. Safety of converting from tetrabenazine to  
350 deutetrabenazine for the treatment of chorea. *JAMA Neurol*.  
351 2017;74(8):977-82.
- 352 [19] Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ.  
353 Tetrabenazine versus deutetrabenazine for Huntington's dis-  
354 ease: Twins or distant cousins? *Mov Disord Clin Pract*.  
355 2017;4(4):582-5.
- 356 [20] Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R,  
357 Gandhi S, et al. Indirect tolerability comparison of Deutetra-  
358 benazine and Tetrabenazine for Huntington disease. *J Clin*  
359 *Mov Disord*. 2017;4:3.
- 360 [21] Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild  
361 EJ. Meta-research metrics matter: Letter regarding article  
362 "indirect tolerability comparison of Deutetrabenazine and  
363 Tetrabenazine for Huntington disease". *J Clin Mov Disord*.  
364 2017;4(9):19.